News & Updates
Filter by Specialty:
Antihypertensive drug does not lower death risk in HFrEF patients
Use of an antihypertensive drug does not appear to reduce the risk of all-cause mortality or hospital readmission in hospitalized older patients with heart failure with reduced ejection fraction (HFrEF) who are receiving contemporary treatments for HF, reveals a recent study.
Antihypertensive drug does not lower death risk in HFrEF patients
08 Jun 2022
Long-term steroid OK for RA but challenges guidelines
Contrary to what current guidelines advocate, long-term use of corticosteroid works fine in older patients with rheumatoid arthritis (RA), suggests the much-anticipated GLORIA* trial presented at EULAR 2022.
Long-term steroid OK for RA but challenges guidelines
08 Jun 2022
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
07 Jun 2022
High-dose iberdomide shows promise in phase II SLE trial
In a phase II trial evaluating three doses of the high-affinity cereblon modulator iberdomide, the 0.45-mg dose demonstrated superiority over placebo for individuals with active, moderate-to-severe systemic lupus erythematosus (SLE).
High-dose iberdomide shows promise in phase II SLE trial
07 Jun 2022
Tenapanor improves symptoms in patients with IBS-C
Treatment with tenapanor improves symptoms in patients with irritable bowel syndrome with constipation (IBS-C) as early as week 1 of treatment, according to two phase III studies presented at DDW 2022.
Tenapanor improves symptoms in patients with IBS-C
07 Jun 2022
Imatinib may reduce mortality in hospitalized COVID-19 patients
The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.